- A Tampa, FL district court rules that Mylan's (MYL +1.6%) Abbreviated New Drug Application (ANDA) seeking approval to sell a delayed-release version of mesalamine infringes on Shire's (SHPG +0.9%) U.S. Patent No. 6,773,720 covering ulcerative colitis med Lialda. Myan will be out of luck until the patent expires in June 2020.
- The company also rebuffed Allergan (AGN +1.7%) on the '720 patent but lost to India's Cadila Healthcare (OTC:CDLYY).
- Source: Bloomberg